OKYO

MKT CAP:$63M

OKYO Pharma Limited

Market Cap

$63M

Healthcare·Biotechnology·🇬🇧 United Kingdom·NASDAQ

Healthcare·Biotechnology·🇬🇧·NASDAQ

Stock Price

$1.64-$0.59 (-26.46%)

Apr 23, 2026

Company Details

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment...

CEO

Robert J. Dempsey

IPO Date

May 17, 2022

Website

www.okyopharma.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$7M

EPS (Diluted)

-$0.43

Free Cash Flow

-$3M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q2 2026

Sep 29, 2025

$0EPS -$0.07

Q4 2025

Mar 30, 2025

$0EPS -$0.04

Q2 2025

Sep 30, 2024

$0EPS -$0.08

FY 2024

Aug 13, 2024

$0EPS -$0.00

Q4 2024

Mar 30, 2024

$0EPS -$0.24

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 17	$0	$0	-$57
Q2 18	$0	$0	-$12.5K
Q4 18	$0	-$159	-$608
Q2 19	$0	-$505	-$587
Q4 19	$0	-$67	-$1.2K
Q2 20	$0	-$210	-$1M
Q4 20	$0	-$5.8K	-$431.0K
Q2 21	$0	-$3.2K	-$1M
Q4 21	$0	-$10.1K	-$3M
Q2 23	$0	-$2.4K	-$4.6K
Q4 23	$0	-$3.9K	-$7.7K
Q2 24	$0	-$4.1K	-$8.7K
Q4 24	$0	-$3.4K	-$7.0K
Q2 25	$0	-$1.3K	-$3M
Q4 25	$0	-$1.3K	-$4M
Q2 26	$0	-$885	-$3M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 17	-$232	-$232
Q2 18	-$70	-$71
Q4 18	-$498	-$497
Q2 19	-$381	-$381
Q4 19	-$381	-$381
Q2 20	-$1M	-$1M
Q4 20	-$326.4K	-$326.4K
Q2 21	-$543.1K	-$545.0K
Q4 21	-$1M	-$1M
Q2 23	-$2.9K	-$2.9K
Q4 23	-$4.2K	-$4.2K
Q2 24	-$6.8K	-$6.8K
Q4 24	-$2.7K	-$2.7K
Q2 25	-$241.5K	-$241.5K
Q4 25	-$2M	-$2M
Q2 26	-$2M	-$2M

Capital Expenditures

Quarter	CapEx
Q4 17	$0
Q2 18	$0
Q4 18	$0
Q2 19	$0
Q4 19	$0
Q2 20	$0
Q4 20	$0
Q2 21	$1.9K
Q4 21	$4.9K
Q2 23	$2
Q4 23	$2
Q2 24	$0
Q4 24	$0
Q2 25	$4
Q4 25	$1.2K
Q2 26	$3

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 17	—	-87.0%
Q2 18	—	+5872.4%
Q4 18	—	+255.6%
Q2 19	—	+348.1%
Q4 19	—	+1921.1%
Q2 20	—	+8634.8%
Q4 20	—	+70788.2%
Q2 21	—	+188963.7%
Q4 21	—	+231410.4%
Q2 23	—	-99.6%
Q4 23	—	-98.2%
Q2 24	—	-99.2%
Q4 24	—	-99.7%
Q2 25	—	+65956.2%
Q4 25	—	+54200.0%
Q2 26	—	+31884.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 17	$0	—
Q2 18	$1	—
Q4 18	$87	—
Q2 19	$0	—
Q4 19	$1.0K	—
Q2 20	$18	—
Q4 20	$12	—
Q2 21	$37	—
Q4 21	$421	—
Q2 23	$569	—
Q4 23	$714	—
Q2 24	$590	—
Q4 24	$4.0K	—
Q2 25	$604	—
Q4 25	$622	—
Q2 26	$0	—

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q4 17	—	$64	—	—
Q2 18	—	$67	$5	—
Q4 18	$212	$67	$5	—
Q2 19	$81	—	—	—
Q4 19	$1.1K	—	—	—
Q2 20	$348.3K	—	—	$747.0K
Q4 20	$167.4K	—	—	$257.7K
Q2 21	$37.0K	—	—	$1M
Q4 21	$139.7K	—	—	$3M
Q2 23	$2.1K	—	—	—
Q4 23	$3.8K	—	—	—
Q2 24	$4.6K	—	—	—
Q4 24	$3.6K	—	—	—
Q2 25	$2M	—	—	$791.7K
Q4 25	$38.4K	—	—	$4M
Q2 26	—	—	—	$3M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 18	$0	$0	$0
Q2 19	$2M	$0	$2M
Q4 19	$627.6K	$0	$627.6K
Q2 20	$67.2K	$0	$67.2K
Q4 20	$235.0K	$0	$235.0K
Q2 21	$7M	$0	$7M
Q4 21	$7M	$0	$7M
Q2 22	$5M	$0	$5M
Q4 22	$3M	$0	$3M
Q2 23	$707.6K	$0	$707.6K
Q4 23	$4M	$0	$4M
Q2 24	$4M	$0	$4M
Q4 24	$826.8K	$0	$826.8K
Q2 25	$987.2K	$0	$987.2K
Q4 25	$2M	$0	$2M
Q2 26	$4M	$0	$4M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 17	6M	0.0%	+1.0%
Q2 18	6M	0.0%	0.0%
Q4 18	6M	+0.9%	+0.9%
Q2 19	8M	+36.1%	+37.4%
Q4 19	8M	+0.1%	+37.5%
Q2 20	9M	+6.0%	+45.7%
Q4 20	10M	+14.4%	+65.3%
Q2 21	10M	+3.8%	+25.9%
Q4 21	11M	+4.0%	+30.9%
Q2 23	22M	+105.1%	+153.3%
Q4 23	23M	+5.7%	+133.9%
Q2 24	26M	+12.4%	+153.5%
Q4 24	33K	-99.9%	-99.7%
Q2 25	34M	+101719.7%	+55.1%
Q4 25	39M	+17.6%	+72.7%
Q2 26	37M	-5.2%	+45.5%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 17	—	—
Q2 18	—	—
Q4 18	—	—
Q2 19	—	—
Q4 19	—	—
Q2 20	—	—
Q4 20	—	—
Q2 21	—	—
Q4 21	—	—
Q2 23	$0	3
Q4 23	$0	3
Q2 24	$0	3
Q4 24	$0	3
Q2 25	$0	3
Q4 25	$0	4
Q2 26	$0	4

Revenue / Employee